Efficacy News and Research

RSS

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

8 Sep 2010

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Clinical trials in a variety of areas within interventional cardiovascular medicine that will be presented at TCT 2010 will directly affect the way that people with cardiovascular disease are treated. Breakthroughs in science and medical research, presented exclusively at TCT, will lead to new treatments that are minimally invasive and involve shorter recovery times. Among the topics being covered are stenting in the femoral artery, polymer-free drug-eluting stents, valves and drug-eluting balloons used in angioplasty.

8 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

STAAR Surgical's Visian Implantable Collamer Lens featured prominently at 2010 ESCRS Congress

STAAR Surgical Company, the leading worldwide developer, manufacturer and marketer of phakic intraocular lenses, today announced that the Visian Implantable Collamer® Lens (ICL) was featured prominently in more than 40 presentations by leading ophthalmologists at meetings prior to and during the 2010 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) held in Paris, France from September 4 through 8, 2010.

8 Sep 2010

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.

8 Sep 2010

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced that Israeli soldiers who suffer severe traumatic brain injury (TBI) can be enrolled in the company's Phase II-b STOP-TBI trials at clinical sites in Israel.

8 Sep 2010

NIH announces $15 million for expansion of Pharmacogenomics Knowledge Base

To help advance research on how genes affect responses to medicines, the National Institutes of Health is spending $15 million over five years to expand a key resource, the Pharmacogenomics Knowledge Base (PharmGKB), http://www.pharmgkb.org/ .

8 Sep 2010

Personalized reminders effective in encouraging seniors to get annual flu shots

Personalized post cards or phone calls can be effective in encouraging more seniors to get their annual flu shots, according to a new review of evidence. Professional facilitators are also successful at urging providers to perform a suite of preventive services, including flu shots for seniors.

8 Sep 2010

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Octapharma AG today announced the imminent start of the biggest ever study of an intravenous immunoglobulin preparation (IVIG) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

8 Sep 2010

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

Synthetic derivative of Retinoic acid can induce cell death

Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25 % of cases and which can lead to death. The development of 4-HPR, a synthetic derivative of RA, has meant a considerable advance due to its greater efficacy compared to its predecessor.

8 Sep 2010

Study finds multivitamins have no impact on cancer recurrence, survival

Patients with colon cancer who used multivitamins during and after being treated with post-surgical chemotherapy did not reduce the risk of the cancer returning or their dying from it, according to researchers at Dana-Farber Cancer Institute.

8 Sep 2010

Bariatric surgery before pregnancy reduces odds of developing gestational diabetes

Obese women who have bariatric surgical procedures before pregnancy were three times less likely to develop gestational diabetes (GDM) than women who have bariatric operations after delivery, according to new research findings published in the August issue of the Journal of the American College of Surgeons. The retrospective study also found that delivery after bariatric procedures was associated with reduced odds of cesarean section-an outcome associated with GDM.

8 Sep 2010

Morning sickness treatment still elusive: Review

According to experts we are nowhere near establishing safe and effective ways to treat morning sickness. Since the Thalidomide disaster in 1960’s that led to severe birth defects in the infants, this area of research is scary and less explored by many researchers. Despite its name, the vomiting and nausea of morning sickness can occur at any time of the day and affect about half of pregnant women. Between 70% and 85% of women will experience nausea during pregnancy, with about half suffering vomiting. Around 2% will experience it so badly they need to be hospitalised.

7 Sep 2010

Also in Global Health News: India's antibiotic use; Abstinence curriculum in China; Child, maternal health in India; Plumpy'nut; PEPFAR funds to Uganda

"The health ministry has formed a committee to frame a policy for antibiotic use, following an uproar over a Lancet study that traced a drug-resistant bacterial superbug's origins to India," LiveMint.com reports. The panel will also look into the "excessive use of antibiotics among Indians," partly fueled by self-medication, that has increased resistance to the drugs. The article notes that the Indian government "rejected the findings of the report" but has "taken note of a lack of policy on antibiotics" (Pandeya, 9/3).

7 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.

7 Sep 2010

Efficacy News and Research

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

STAAR Surgical's Visian Implantable Collamer Lens featured prominently at 2010 ESCRS Congress

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

NIH announces $15 million for expansion of Pharmacogenomics Knowledge Base

Personalized reminders effective in encouraging seniors to get annual flu shots

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Silence Therapeutics receives two patents for RNA interference therapeutics

Synthetic derivative of Retinoic acid can induce cell death

Study finds multivitamins have no impact on cancer recurrence, survival

Bariatric surgery before pregnancy reduces odds of developing gestational diabetes

Morning sickness treatment still elusive: Review

Also in Global Health News: India's antibiotic use; Abstinence curriculum in China; Child, maternal health in India; Plumpy'nut; PEPFAR funds to Uganda

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News